ReviewTranslational neurodegeneration2016
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease.
Review in Translational neurodegeneration, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Global trends of early-onset Parkinson's disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.Frontiers in neurology · 2025Pooled it
- Transcutaneous vagus nerve stimulation for Parkinson's disease: a systematic review and meta-analysis.Frontiers in aging neuroscience · 2024Pooled it
- Efficacy of pramipexole on quality of life in patients with Parkinson's disease: a systematic review and meta-analysis.BMC neurology · 2022Pooled it
- Altered white matter microarchitecture in Parkinson's disease: a voxel-based meta-analysis of diffusion tensor imaging studies.Frontiers of medicine · 2021Pooled it
- Trial
- Continuous Dopaminergic Stimulation-Based Levodopa Treatment in Patients with Early to Mid-Stage Parkinson's Disease: A Systematic Review and Meta-Analysis.Neurology and therapy · 2025Review
- Development and validation of a Wechat mini app-based screening tool (eR-BFAS) for early detection of Parkinson's disease.Aging clinical and experimental research · 2025Article
- Utilizing combined quantitative multiparametric MRI as potential biomarkers for improved early-stage parkinson's disease diagnosis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Deep Brain Stimulation in Parkinson's Disease Patients Over 75 Years of Age: A Single-Institution Retrospective Analysis.CNS neuroscience & therapeutics · 2025Article
- Insomnia in Parkinson's Disease: Causes, Consequences, and Therapeutic Approaches.Molecular neurobiology · 2025Review
- A simple and effective screening strategy for early multiple system atrophy diagnosis and α-Synuclein forms in erythrocytes.Frontiers in aging neuroscience · 2025Article
- Association betweenFrontiers in genetics · 2025Article
- Brain functional network abnormalities in Parkinson's disease patients at different disease stages.Frontiers in neuroscience · 2025Article
- Acupuncture for early Parkinson's disease with mild to moderate depression: a randomized controlled trial protocol with functional MRI.Frontiers in neurology · 2024Article
- Potentially inappropriate medications among older patients with Parkinson's disease: a cross-sectional analysis of a national health insurance database in China.BMC geriatrics · 2023Article
- Mesenchymal stromal cell biotherapy for Parkinson's disease premotor symptoms.Chinese neurosurgical journal · 2023Review
- Analysis of phenolic compounds in Parkinson's disease: a bibliometric assessment of the 100 most cited papers.Frontiers in aging neuroscience · 2023Review
- Clinical characteristics and outcome of COVID-19 patients with Parkinson's disease: a hospital-based case-control study in Shanghai, China.Frontiers in aging neuroscience · 2023Article
- Cortical atrophy is associated with cognitive impairment in Parkinson's disease: a combined analysis of cortical thickness and functional connectivity.Brain imaging and behavior · 2022Article
- Brain functional network abnormalities in parkinson's disease with mild cognitive impairment.Cerebral cortex (New York, N.Y. : 1991) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 20 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) is a chronic, progressive and debilitating disease, which affects over 2.5 million people in China. PD is characterized clinically by resting tremor, muscular rigidity, bradykinesia and postural instability. As the disease progresses, additional complications can arise such as non-motor and neurobehavioral symptoms. Pharmacological treatment and surgical intervention for PD have been implemented in China. Until 10 years ago, there was lack of standardization for the management of PD in different regions and among different physicians, leading to different treatment levels in different regions and different physicians. Since then, the Chinese Parkinson's Disease and Movement Disorder Society have published three versions of guidelines for the management of PD in China, in 2006, 2009 and 2014, respectively. Correspondingly, the overall level of treatment for PD in China improved.
objectivesTo update the treatment guidelines based on current foreign and domestic practice guidelines and clinical evidence, and to improve the treatment options available to physicians in the management of PD. SUMMARY: A variety of treatment recommendations in the treatment guidelines have been proposed, including physical activity and disease-modifying medication, which should be initiated at the early-stage of the disease. The principles of dosage titration should be followed to avoid acute adverse reactions to the drugs, to achieve a satisfactory clinical effect with a low dose and to reduce the incidence of long-term motor complications. Moreover, different treatment strategies should be considered at different stages of the disease. Importantly, treatment guidelines and personalized treatments should be valued equally. A set of treatment recommendations has been developed to assist physicians to improve and optimize clinical outcomes for patients with PD in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.